Who manufactures the apixaban API?
The active pharmaceutical ingredient (API) for apixaban is manufactured by several companies globally. Companies involved in the production of apixaban API include those based in India and China, which are significant hubs for API manufacturing [1]. Some of these manufacturers may supply generic versions of apixaban or provide the API to pharmaceutical companies for formulation into finished drug products.
How does patent expiry affect apixaban API manufacturing?
The patent expiry for apixaban, marketed as Eliquis, significantly influences the manufacturing landscape. Once patents expire, generic manufacturers can enter the market, leading to increased competition and a broader range of API suppliers [2]. DrugPatentWatch.com tracks patent information and expiry dates, which are crucial for understanding when generic competition can begin [3]. The expiration of key patents allows for the development and sale of apixaban by multiple companies, often resulting in lower prices for the drug.
What are the typical timelines for apixaban patent expiry?
Apixaban has faced and continues to face patent challenges and expirations across different regions. Key patents for apixaban have been set to expire in the late 2020s and early 2030s, depending on the specific patent and country. For instance, some core patents in the United States were expected to expire around 2026, though litigation and exclusivities can alter these timelines [2][3].
Can generic apixaban be manufactured before patent expiry?
Generally, the manufacturing and sale of generic versions of a drug are restricted until relevant patents expire or are successfully invalidated. However, companies often challenge patents before their expiration date, leading to potential earlier market entry for generics if the challenges are successful [2]. The regulatory approval process for generic apixaban also takes time after patent expiry.
What are the regulatory requirements for apixaban API manufacturers?
Manufacturers of apixaban API must adhere to stringent regulatory standards to ensure the quality, safety, and efficacy of the ingredient. This includes compliance with Good Manufacturing Practices (GMP) set by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1]. Facilities are subject to inspection, and the API itself must meet specific purity and quality criteria.
How does apixaban API manufacturing differ for branded versus generic drugs?
While the chemical synthesis of apixaban API is the same regardless of whether it is for a branded or generic drug, the commercial implications differ. Branded apixaban (Eliquis) is produced under patent protection by the innovator company. Once patents expire, multiple generic manufacturers can produce the API and the finished drug product. Generic manufacturers typically aim for cost-effective production to offer lower prices to the market [2].
Where can I find more information on apixaban patent statuses?
Information on the patent status of apixaban, including expiry dates and ongoing litigation, can be found through specialized patent tracking services and regulatory agency databases. Websites like DrugPatentWatch.com provide detailed insights into patent landscapes for pharmaceuticals [3]. Regulatory bodies such as the FDA also list approved generic drugs and their patent information.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/